Search Results - "Kaupe, Ines"

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets by Rix, Uwe, Hantschel, Oliver, Dürnberger, Gerhard, Remsing Rix, Lily L., Planyavsky, Melanie, Fernbach, Nora V., Kaupe, Ines, Bennett, Keiryn L., Valent, Peter, Colinge, Jacques, Köcher, Thomas, Superti-Furga, Giulio

“…The BCR-ABL tyrosine kinase inhibitor imatinib represents the current frontline therapy in chronic myeloid leukemia. Because many patients develop imatinib…”
Get full text

A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain by Wojcik, John, Hantschel, Oliver, Grebien, Florian, Kaupe, Ines, Bennett, Keiryn L, Barkinge, John, Jones, Richard B, Koide, Akiko, Superti-Furga, Giulio, Koide, Shohei

“…SH2 domains are present in many proteins, and designing specific inhibitors has been a challenge. Now a monobody, based on a fibronectin type III domain…”
Get full text

Charting the molecular network of the drug target Bcr-Abl by Brehme, Marc, Hantschel, Oliver, Colinge, Jacques, Kaupe, Ines, Planyavsky, Melanie, Köcher, Thomas, Mechtler, Karl, Bennett, Keiryn L, Superti-Furga, Giulio

“…The tyrosine kinase Bcr-Abl causes chronic myeloid leukemia and is the cognate target of tyrosine kinase inhibitors like imatinib. We have charted the…”
Get full text

The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr–Abl activity in chronic myeloid leukemia by Hantschel, Oliver, Gstoettenbauer, Agnes, Colinge, Jacques, Kaupe, Ines, Bilban, Martin, Burkard, Thomas R., Valent, Peter, Superti-Furga, Giulio

“…We have identified differentially regulated genes in chronic myeloid leukemia (CML) cells upon short treatment with the broad-spectrum Bcr–Abl inhibitor…”
Get full text

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia by Hantschel, Oliver, Warsch, Wolfgang, Eckelhart, Eva, Kaupe, Ines, Grebien, Florian, Wagner, Kay-Uwe, Superti-Furga, Giulio, Sexl, Veronika

“…Although JAK2 inhibitors were proposed to be beneficial in chronic myeloid leukemia, myeloid transformation and STAT5 activation in BCR-ABL–positive leukemias…”
Get full text

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis by Grebien, Florian, Hantschel, Oliver, Wojcik, John, Kaupe, Ines, Kovacic, Boris, Wyrzucki, Arkadiusz M., Gish, Gerald D., Cerny-Reiterer, Sabine, Koide, Akiko, Beug, Hartmut, Pawson, Tony, Valent, Peter, Koide, Shohei, Superti-Furga, Giulio

“…Chronic myelogenous leukemia (CML) is caused by the constitutively active tyrosine kinase Bcr-Abl and treated with the tyrosine kinase inhibitor (TKI)…”
Get full text

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib by Sherbenou, Daniel W., Hantschel, Oliver, Kaupe, Ines, Willis, Stephanie, Bumm, Thomas, Turaga, Lalita P., Lange, Thoralf, Dao, Kim-Hien, Press, Richard D., Druker, Brian J., Superti-Furga, Giulio, Deininger, Michael W.

“…Point mutations in the kinase domain of BCR-ABL are the most common mechanism of drug resistance in chronic myeloid leukemia (CML) patients treated with ABL…”
Get full text

Initial characterization of the human central proteome by Burkard, Thomas R, Planyavsky, Melanie, Kaupe, Ines, Breitwieser, Florian P, Bürckstümmer, Tilmann, Bennett, Keiryn L, Superti-Furga, Giulio, Colinge, Jacques

“…On the basis of large proteomics datasets measured from seven human cell lines we consider their intersection as an approximation of the human central…”
Get full text

Structural Positioning of the SH2 Domain Is Critical for Bcr-Abl Kinase Activity, Signal Transduction and Oncogenic Transformation by Hantschel, Oliver D., Grebien, Florian, Kaupe, Ines, Superti-Furga, Giulio

“…We have recently shown that the SH2 domain stimulates c-Abl catalytic activity and substrate phosphorylation. This effect is exerted directly through the…”
Get full text

Bcr-Abl Directly Activates Stat5 Independent of Jak2 by Hantschel, Oliver D., Eckelhart, Eva, Kaupe, Ines, Grebien, Florian, Wagner, Kay-Uwe, Sexl, Veronika, Superti-Furga, Giulio

“…Abstract 511 Persistent activation of the transcription factor Stat5 is a signaling hallmark of Chronic Myelogenous Leukemia (CML). In mouse models, Stat5 was…”
Get full text

Abstract 5128: Physical EGFR network mapping and dynamic regulation in lung cancer cells by Li, Jiannong, Bennett, Keiryn, Song, Lanxi, Bai, Yun, Yoshida, Takeshi, Edwards, Arthur, Kinose, Fumi, Fang, Bin, Zhang, Guolin, Kaupe, Ines, Greben, Florian, Superti-Furga, Giulio, Haura, Eric

“…Aberrant activation of Epidermal Growth Factor Receptor (EGFR) through somatic mutations plays a critical role in the development and progression in lung…”
Get full text

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis by Grebien, Florian, Hantschel, Oliver, Wojcik, John, Kaupe, Ines, Kovacic, Boris, Wyrzucki, Arkadiusz M., Gish, Gerald D., Cerny-Reiterer, Sabine, Koide, Akiko, Beug, Hartmut, Pawson, Tony, Valent, Peter, Koide, Shohei, Superti-Furga, Giulio

Get full text

The Bcr-Abl SH2-Kinase Domain Interface Is Critical for Leukemogenesis and An Additional Therapeutic Target in CML by Hantschel, Oliver D., Grebien, Florian, Kaupe, Ines, Kovacic, Boris, Wojcik, John, Gish, Gerald D, Koide, Shohei, Beug, Hartmut, Pawson, Tony, Superti-Furga, Giulio

“…Abstract 37 We previously showed that the Abl SH2 domain is an allosteric activator of c-Abl tyrosine kinase activity and substrate phosphorylation…”
Get full text

Systematic Profiling and Novel Targets of the Bcr-Abl Kinase Inhibitors Imatinib, Nilotinib and Dasatinib by Hantschel, Oliver, Rix, Uwe, Buerckstuemmer, Tilmann, Schmidt, Uwe, Kneidinger, Michael, Bennett, Keiryn L., Kaupe, Ines, Ellmeier, Wilfried, Valent, Peter, Superti-Furga, Giulio

“…The BCR-ABL tyrosine kinase inhibitor imatinib represents the current frontline therapy in chronic myeloid leukemia (CML). Since imatinib resistance has become…”
Get full text

Characterization of BCR-ABL Deletion Mutants from Patients with Chronic Myeloid Leukemia by Sherbenou, Daniel W., Hantschel, Oliver J., Turaga, Lalita, Mag, Ines Kaupe, Willis, Stephanie, Bumm, Thomas, Press, Richard D., Superti-Furga, Giulio, Druker, Brian J., Deininger, Michael W.

“…Background: The Bcr-Abl tyrosine kinase causes chronic myeloid leukemia and is the target for imatinib therapy. During imatinib treatment, in some patients…”
Get full text

Experimental characterization of the human non-sequence-specific nucleic acid interactome by Dürnberger, Gerhard, Bürckstümmer, Tilmann, Huber, Kilian, Giambruno, Roberto, Doerks, Tobias, Karayel, Evren, Burkard, Thomas R, Kaupe, Ines, Müller, André C, Schönegger, Andreas, Ecker, Gerhard F, Lohninger, Hans, Bork, Peer, Bennett, Keiryn L, Superti-Furga, Giulio, Colinge, Jacques

“…BACKGROUND: The interactions between proteins and nucleic acids have a fundamental function in many biological processes, including gene transcription, RNA…”
Get full text